Palmitoylethanolamide

Palmitoylethanolamide (PEA), also known as palmidrol, is an endogenous fatty acid amide of the N-acylethanolamine class, the same family that includes the endocannabinoid anandamide ^[2]. The body makes PEA on demand within cell membranes, and it is also present in foods such as egg yolk, soybeans, and milk. Despite its structural resemblance to endocannabinoids, PEA does not bind the classical cannabinoid receptors CB1 and CB2, and it is instead regarded as a lipid signaling molecule and regulator of inflammation ^[1][2].

PEA is best understood as an activator of the nuclear receptor PPAR-alpha, through which it turns down the transcription of pro-inflammatory genes, and it also appears to restrain the activation of mast cells and other immune cells that amplify pain and inflammation ^[1]. On the strength of these actions it has been investigated for a range of conditions marked by chronic pain and nerve involvement, including peripheral neuropathy, where controlled and preclinical studies describe both pain relief and protection of nerve tissue ^[1][4]. Reviews have extended this interest to the central nervous system and to conditions such as neurodegeneration and, more tentatively, autism spectrum disorder ^[2][3].

Commercially, PEA is supplied as a dietary supplement and, in some countries, as a food for special medical purposes, often in micronized or ultra-micronized forms designed to improve absorption ^[4]. It is generally regarded as well tolerated, with analyses reporting a low rate of adverse effects and no notable drug interactions ^[1]. Because it is not licensed as a conventional medicine in most places, its regulatory status varies by region, and much of the supporting evidence comes from small trials and laboratory research rather than large definitive studies ^[3].

Palmitoylethanolamide (PEA) has an unusually clean safety record; across more than twenty clinical trials involving roughly 2,000 patients, and a meta-analysis of ten RCTs at 300 to 1200 mg/day for up to six months, no serious adverse effects were reported. The rare events that do appear are mild and self-limiting, such as brief stomach discomfort, transient drowsiness, or short-lived palpitations in isolated participants. Being an endogenous fatty-acid amide, it is well tolerated and available data through roughly seven weeks argue against serious adverse drug reactions at a rate of 1 in 200 or greater. The honest limits are the usual ones: robust long-term (multi-year) data are thin, and safety in pregnancy and breastfeeding is not established. No significant drug-interaction contraindications are documented, though prudence with other agents is reasonable.